These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30054667)

  • 41. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
    Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
    Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of regulatory T-cells in glioma immunology.
    Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
    Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
    Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
    Murphy KA; Lechner MG; Popescu FE; Bedi J; Decker SA; Hu P; Erickson JR; O'Sullivan MG; Swier L; Salazar AM; Olin MR; Epstein AL; Ohlfest JR
    Clin Cancer Res; 2012 Sep; 18(17):4657-68. PubMed ID: 22781551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
    Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS
    Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-Based Immunotherapy of Gliomas.
    Everson RG; Antonios JP; Liau LM
    Prog Neurol Surg; 2018; 32():90-100. PubMed ID: 29990977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.
    Grauer OM; Nierkens S; Bennink E; Toonen LW; Boon L; Wesseling P; Sutmuller RP; Adema GJ
    Int J Cancer; 2007 Jul; 121(1):95-105. PubMed ID: 17315190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches.
    Akasaki Y; Black KL; Yu JS
    Front Biosci; 2005 Sep; 10():2908-21. PubMed ID: 15970545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
    Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P
    Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy for malignant gliomas.
    Bloch O
    Cancer Treat Res; 2015; 163():143-58. PubMed ID: 25468230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M; Han S; Shi X
    Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
    Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
    Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cellular immunity in the treatment of brain tumors.
    Wheeler CJ; Yu JS; Black KL
    Clin Neurosurg; 2004; 51():132-9. PubMed ID: 15571138
    [No Abstract]   [Full Text] [Related]  

  • 58. Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.
    Müller K; Henke G; Pietschmann S; van Gool S; De Vleeschouwer S; von Bueren AO; Compter I; Friedrich C; Matuschek C; Klautke G; Kortmann RD; Hundsberger T; Baumert BG
    J Neurooncol; 2015 Sep; 124(2):325-32. PubMed ID: 26070556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cell-based immunotherapy of malignant gliomas.
    Parajuli P; Sloan AE
    Cancer Invest; 2004; 22(3):405-16. PubMed ID: 15493362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study.
    Chen PY; Hsieh HY; Huang CY; Lin CY; Wei KC; Liu HL
    J Transl Med; 2015; 13():93. PubMed ID: 25784614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.